Amneal Pharmaceuticals (STU:2DT) Beneish M-Score: -2.69 (As of Jul. 08, 2026)


STU:2DT Amneal Pharmaceuticals Inc STU:2DT
61 GF Score
Price €14.90
GF Value €6.55
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Amneal Pharmaceuticals Beneish M-Score?

Amneal Pharmaceuticals STU:2DT +0.68% 61 Beneish M-Score is -2.69 as of Jul. 08, 2026. GuruFocus rates STU:2DT with a GF Score™ of 61/100 and a GF Value™ of €6.55 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 910 Drug Manufacturers companies, Amneal Pharmaceuticals ranks better than 67.47% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.69 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Amneal Pharmaceuticals's Beneish M-Score or its related term are showing as below:

STU:2DT' s Beneish M-Score Range Over the Past 10 Years
Min: -3.47   Med: -2.74   Max: -2.24
Current: -2.69

During the past 10 years, the highest Beneish M-Score of Amneal Pharmaceuticals was -2.24. The lowest was -3.47. And the median was -2.74.


Amneal Pharmaceuticals Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Amneal Pharmaceuticals's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amneal Pharmaceuticals Beneish M-Score Chart

Amneal Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.78 -2.24 -3.20 -2.69 -2.76

Amneal Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.80 -2.94 -2.83 -2.76 -2.69

STU:2DT vs INDV, KNSA, LQDA: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Amneal Pharmaceuticals's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amneal Pharmaceuticals Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amneal Pharmaceuticals's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Amneal Pharmaceuticals's Beneish M-Score falls into.


STU:2DT
61GF Score
Amneal Pharmaceuticals Inc STU:2DT
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amneal Pharmaceuticals Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Amneal Pharmaceuticals for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0583+0.528 * 0.9479+0.404 * 0.8446+0.892 * 0.9966+0.115 * 1.1766
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0547+4.679 * -0.053585-0.327 * 0.975
=-2.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was €781 Mil.
Revenue was 624.979 + 695.428 + 668.405 + 628.148 = €2,617 Mil.
Gross Profit was 276.898 + 253.8 + 233.426 + 248.181 = €1,012 Mil.
Total Current Assets was €1,555 Mil.
Total Assets was €3,062 Mil.
Property, Plant and Equipment(Net PPE) was €483 Mil.
Depreciation, Depletion and Amortization(DDA) was €178 Mil.
Selling, General, & Admin. Expense(SGA) was €470 Mil.
Total Current Liabilities was €630 Mil.
Long-Term Debt & Capital Lease Obligation was €2,314 Mil.
Net Income was 53.851 + 29.955 + 2.018 + 19.436 = €105 Mil.
Non Operating Income was -9.707 + -2.588 + 15.736 + 4.167 = €8 Mil.
Cash Flow from Operations was -23.133 + 111.289 + 100.919 + 72.671 = €262 Mil.
Total Receivables was €740 Mil.
Revenue was 643.263 + 697.645 + 632.924 + 651.954 = €2,626 Mil.
Gross Profit was 236.699 + 251.044 + 242.872 + 232.201 = €963 Mil.
Total Current Assets was €1,397 Mil.
Total Assets was €3,113 Mil.
Property, Plant and Equipment(Net PPE) was €484 Mil.
Depreciation, Depletion and Amortization(DDA) was €224 Mil.
Selling, General, & Admin. Expense(SGA) was €447 Mil.
Total Current Liabilities was €995 Mil.
Long-Term Debt & Capital Lease Obligation was €2,074 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(780.794 / 2616.96) / (740.272 / 2625.786)
=0.298359 / 0.281924
=1.0583

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(962.816 / 2625.786) / (1012.305 / 2616.96)
=0.366677 / 0.386825
=0.9479

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (1555.19 + 483.329) / 3062.289) / (1 - (1397.166 + 483.542) / 3112.855)
=0.334315 / 0.395825
=0.8446

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=2616.96 / 2625.786
=0.9966

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(223.551 / (223.551 + 483.542)) / (177.588 / (177.588 + 483.329))
=0.316155 / 0.268699
=1.1766

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(470.346 / 2616.96) / (447.446 / 2625.786)
=0.17973 / 0.170405
=1.0547

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((2313.877 + 629.762) / 3062.289) / ((2073.81 + 995.137) / 3112.855)
=0.961254 / 0.985895
=0.975

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(105.26 - 7.608 - 261.746) / 3062.289
=-0.053585

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Amneal Pharmaceuticals has a M-score of -2.75 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.69 mean?
Amneal Pharmaceuticals (STU:2DT) has a Beneish M-Score of -2.69 as of Jul. 08, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Amneal Pharmaceuticals and its competitors. According to the industry distribution chart, Amneal Pharmaceuticals ranks #296 out of 910 companies in the Drug Manufacturers industry, placing it in the top 32.5%.
Is Amneal Pharmaceuticals' Beneish M-Score too high?
Amneal Pharmaceuticals' current Beneish M-Score is -2.69. Based on the distribution chart, Amneal Pharmaceuticals ranks #296 out of 910 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Amneal Pharmaceuticals has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Amneal Pharmaceuticals' Beneish M-Score compare to INDV and KNSA?
According to the Drug Manufacturers industry distribution chart, Amneal Pharmaceuticals ranks #296 out of 910 companies for Beneish M-Score. This puts Amneal Pharmaceuticals in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Amneal Pharmaceuticals and its competitors. Amneal Pharmaceuticals's current Beneish M-Score is -2.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amneal Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Amneal Pharmaceuticals (STU:2DT) is currently considered Significantly Overvalued. The stock's GF Value™ is €6.55, compared to a current price of €14.90 — trading 127.5% above its estimated fair value. The current Beneish M-Score is -2.69. Amneal Pharmaceuticals' overall GF Score™ is 61/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Amneal Pharmaceuticals (STU:2DT), the current Beneish M-Score is -2.69 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Amneal Pharmaceuticals (STU:2DT) Overvalued in 2026?

Based on GuruFocus' analysis, Amneal Pharmaceuticals stock appears to be overvalued. The current stock price of €14.90 is trading 127.5% above its estimated GF Value™ of €6.55. GuruFocus considers Amneal Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for STU:2DT:

  • Beneish M-Score: -2.69
  • GF Value™: €6.55 vs. price of €14.90 (127.5% above fair value)
  • GF Score™: 61/100 with 6 warning signs

No single metric tells the full story. See the STU:2DT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Amneal Pharmaceuticals Business Description

Other Exchanges AMRX:USA
Address 400 Crossing Boulevard, 3rd Floor, Bridgewater, NJ, USA, 08807
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
61GF Score

Get the complete analysis for STU:2DT

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€14.90
Price
€6.55
GF Value